NASDAQ:UTHR - United Therapeutics Stock Price, Forecast & News

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

United Therapeutics Co. (NASDAQ:UTHR) released its earnings results on Wednesday, October, 30th. The biotechnology company reported $3.16 earnings per share for the quarter, beating the consensus estimate of $2.34 by $0.82. The biotechnology company had revenue of $401.50 million for the quarter, compared to the consensus estimate of $342.28 million. United Therapeutics had a negative return on equity of 3.54% and a negative net margin of 6.04%. The business's quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter last year, the business posted $3.98 earnings per share. View United Therapeutics' Earnings History.

United Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for United Therapeutics.

United Therapeutics will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

11 equities research analysts have issued twelve-month price targets for United Therapeutics' stock. Their forecasts range from $80.00 to $237.00. On average, they anticipate United Therapeutics' share price to reach $118.27 in the next twelve months. This suggests a possible upside of 10.6% from the stock's current price. View Analyst Price Targets for United Therapeutics.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 2 sell ratings, 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for United Therapeutics.

News coverage about UTHR stock has been trending somewhat positive on Saturday, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. United Therapeutics earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for United Therapeutics.

Some companies that are related to United Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), Celgene (CELG), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), General Electric (GE), NVIDIA (NVDA), Nektar Therapeutics (NKTR), Johnson & Johnson (JNJ), AT&T (T) and Netflix (NFLX).

United Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (8.08%), FMR LLC (5.43%), State Street Corp (4.32%), Palo Alto Investors LP (2.94%), Acadian Asset Management LLC (1.80%) and AQR Capital Management LLC (1.53%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

UTHR stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Palo Alto Investors LP, Krensavage Asset Management LLC, Schonfeld Strategic Advisors LLC, UBS Group AG, Bank of New York Mellon Corp, Acadian Asset Management LLC and Rafferty Asset Management LLC. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Patusky, Raymond Dwek and Richard Giltner. View Insider Buying and Selling for United Therapeutics.

UTHR stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, AJO LP, FMR LLC, Prudential Financial Inc., AQR Capital Management LLC, DNB Asset Management AS, Bank of America Corp DE and AXA. View Insider Buying and Selling for United Therapeutics.

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of UTHR stock can currently be purchased for approximately $106.96.

United Therapeutics has a market capitalization of $4.69 billion and generates $1.63 billion in revenue each year. The biotechnology company earns $589.20 million in net income (profit) each year or $13.39 on an earnings per share basis. United Therapeutics employs 860 workers across the globe.View Additional Information About United Therapeutics.

The official website for United Therapeutics is http://www.unither.com/.

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]